GS JT (Votrient pazopanib 200 mg)
Generic Name: pazopanib
Pill with imprint GS JT is Gray, Capsule-shape and has been identified as Votrient pazopanib 200 mg. It is supplied by GlaxoSmithKline.
Votrient is used in the treatment of renal cell carcinoma; soft tissue sarcoma and belongs to the drug class VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Votrient pazopanib 200 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for GS JT
Votrient
- Generic Name:
- pazopanib
- Imprint:
- GS JT
- Strength:
- pazopanib 200 mg
- Color:
- Gray
- Size:
- 14.00 mm
- Shape:
- Capsule-shape
- Availability:
- Prescription only
- Drug Class:
- VEGF/VEGFR inhibitors
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- GlaxoSmithKline
- Inactive Ingredients:
- magnesium stearate
microcrystalline cellulose
povidone
sodium starch glycolate type A potato
hypromelloses
ferrosoferric oxide
polyethylene glycol 400
polysorbate 80
titanium dioxide
Note: Inactive ingredients may vary.
Other Labelers / Repackagers:
| NDC Code | Labeler / Repackager |
|---|---|
| 00078-0670 | Novartis Pharmaceuticals Corporation |
More about Votrient (pazopanib)
- Votrient Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 64 Reviews
- Drug class: VEGF/VEGFR inhibitors
Consumer resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
